Topic: disease awareness

August 1st, 2016

Living with Psoriasis: “How a Painful Disease Inspired Me to Advocate for Others”

By Howard H. Chang

PsoriasisIt’s hard for a child to even begin to fathom the impact that being diagnosed with a chronic illness might have on him over the course of a lifetime. When I was diagnosed with psoriasis at eight years old, I only understood that life as I knew it had changed—and not for the better.

Psoriasis is an autoimmune disease that causes raised, red, scaly patches to appear on the skin. And according to the National Psoriasis Foundation, it affects about 125 million worldwide.

Although it is not contagious, psoriasis can be associated with a host of other health conditions, including depression, anxiety, cardiovascular disease, cancer, arthritis and diabetes, among others.

Saturday cartoons and superhero action figures filled my life until psoriasis treatments took over. I hated the messy topical treatments—like awful-smelling coal tar—that I had to put on before bed. I also had to get phototherapy treatments three times a week, which required standing in a booth to expose the psoriatic skin to a dose of ultraviolet light—not exactly the way an elementary school boy wanted to spend his time.

Suffering Alone and in Silence
Psoriasis is a stigmatizing condition. On top of the physical symptoms and potential comorbidities, I faced all kinds of social rejection due to the red, flaky, inflamed, disfigured skin that covered my body.

Read More

April 27th, 2016

Dengue: A Global Public Health Threat That Deserves Attention

By Dr. Marnix Van Loock, Dengue Team Leader, Global Public Health

Aedes aegypti mosquito

The dengue virus is transmitted primarily by the Aedes aegypti mosquito.

With the World Health Organization (WHO) recently declaring the Zika virus a “public health emergency of international concern,” the risk of vector-borne diseases, which are transmitted by insects like mosquitoes, has been catapulted into the global spotlight.

So not surprisingly, the topic was high on the agenda when I joined a group of experts at the International Society of Neglected Tropical Diseases’ annual conference, ISNTD Bites, last month.

Along with sharing the latest research, disease modelling and surveillance technologies, our task was to find ways to promote even greater collaboration between the many parties involved in the control of vector-borne diseases. With many of these diseases—like Zika—emerging rapidly, it’s a huge and on-going challenge.

Facts About the Dengue Virus
I was at the conference to talk about our dengue program, an important part of our commitment to Global Public Health within the Johnson & Johnson Janssen Pharmaceutical Companies.

Much like Zika, dengue is a vector-borne disease that has not been widely known. It’s also a virus that infects nearly 400 million people each year, causing such symptoms as a fever, rash and muscle and joint pain.

Read More

February 11th, 2016

6 Things Everyone Should Know About the Zika Virus

By Liz Ozaist, Global Content Lab Editor-in-Chief
zika virus

Zika. It’s a word that has dominated the headlines for months. And it’s likely to continue to be a part of the news cycle for months to come.

According to the Centers for Disease Control and Prevention, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infection in Brazil last May. Since then, the virus has spread throughout Central and South America—and even the United States.

Earlier this year, the first known case of Zika was reported in Texas by local health officials, and the virus was declared an international health emergency by the World Health Organization (WHO).

It’s a lot to digest, and it’s likely leaving a lot of people asking: So what do I really need to know about this virus?

Zika is spread through mosquito bites, causing such symptoms as fever, rash, joint pain and conjunctivitis. Unborn children are particularly at risk because the virus has been linked to birth defects, including Guillain-Barré syndrome, which can result in muscle weakness and even paralysis.

Johnson & Johnson has a long-standing commitment to mobilizing to help address such public health crises—and the Zika virus is no exception.

Read More

October 28th, 2015

Janssen Recognizes World Psoriasis Day

This October 29th, the Janssen Pharmaceutical Companies of Johnson & Johnson join the International Federation of Psoriasis Associations in support of World Psoriasis Day, an annual event dedicated to raising awareness of an autoimmune disease that affects 125 million people worldwide.

At Janssen, our commitment to people living with psoriatic disease has never been stronger, both through the medicines that we offer today and through our continued research and development to advance the next generation of therapies for the future.

We are motivated to go further by the personal impact of psoriasis and psoriatic arthritis, pursuing approaches that will hopefully one day intercept and even prevent psoriatic disease altogether.

Every day, these efforts bring us closer to realizing our vision of #aworldfreefrom immune and inflammatory diseases, an aspirational goal but one that we believe is achievable for people living with or who may develop psoriatic disease in the future.


Anne Fourie2

Anne Fourie, PhD, is Disease Area Leader, Psoriasis, Janssen Research & Development, LLC

 

 

irene HsuIrene Hsu, PharmD, MBA, is Vice President, Commercial Disease Area Leader, Rheumatoid Arthritis and Psoriasis, Janssen Pharmaceutical Companies of Johnson & Johnson.

 

 

 

Read More

October 11th, 2015

Janssen Recognizes World Arthritis Day

Today, October 12th, the Janssen Pharmaceutical Companies of Johnson & Johnson stand with the European League Against Rheumatism in support of World Arthritis Day, an annual event to raise awareness of rheumatic and musculoskeletal diseases.

At Janssen, we understand the impact that conditions like rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis have each and every day on patients and their loved ones. For the past twenty years, we have made it our mission to address these challenges through the development of advanced biologic therapies. While these important medicines have changed the way these diseases are treated, we still strive to do for more patients.

Today, our scientists are advancing the latest research to discover and develop the next generation of medicines that will provide new, more personalized approaches in addressing individual patient needs. We look to the future, motivated by the successes we have seen over the years, and inspired by the challenges we recognize still exist for many people living with the pain, inflammation and limitations associated with rheumatic diseases.

As we look to the future, we envision #aworldfreefrom immune and inflammatory diseases like RA. That’s our vision and, today, on World Arthritis Day, our global Janssen team is taking action in advancing science to help those living with rheumatic and musculoskeletal diseases today and in the future.

Read More

October 9th, 2015

Prostate Cancer: Living, Not Just Surviving

By Jane Griffiths, Company Group Chairman, Janssen EMEA and Executive Sponsor, Janssen Sustainability Council

Janssen report focuses on quality of life for prostate cancer survivors

Prostate Cancer: Living, Not Just SurvivingMore than three million men in Europe have prostate cancer and almost half of them have lived with the disease for five years or more, according to European Commission. Advances in the management of prostate cancer means that more patients are beating the disease and looking ahead at what it means to live as a survivor.

To bring focus to the issues facing prostate cancer survivors, the team at Janssen recently launched the Prostate Cancer: Living, not Just Surviving report, summarizing findings of a pan-European survey of prostate cancer patients, caregivers and healthcare professionals looking at the physical, emotional and social impact of prostate cancer. Some key findings in the report include:[i]

  • Fatigue (66%) has the biggest negative impact on patients reporting chronic physical effects from the disease, over disability and pain (41% and 22% respectively)
  • Prostate cancer patients are more likely to worry about intimacy problems (54%) than dying (36%), however nearly two-thirds (62%) of patients are not willing to talk about such intimacy problems with their partner
  • In prostate cancer patients:
    • 80% are unable to do activities they used to enjoy before diagnosis
    • 85% are unable to be intimate with their partner following diagnosis
  • Only 14 percent of healthcare professionals feel that they have sufficient resources to address these types of quality of life issues

This launch is the culmination of more than two years’ work, involving many patient organisations from across Europe.

Read More

October 5th, 2015

Policies that Underestimate NCDs Could Blunt Economic Growth in Asia

By Kris Sterkens, Company Group Chairman, Janssen, the pharmaceutical companies of Johnson & Johnson, Asia Pacific

A new report from the EcoShifting Landscape of HC in AP_Page_1nomist – The Shifting Landscape of Healthcare in Asia Pacific confirms that people in our region are living longer, but not necessarily healthier, with overburdened, provider-led healthcare systems that lack comprehensive strategies to address emerging non-communicable diseases (NCDs) such as cancer, diabetes and mental illness.

We provided a grant for the development of this independent research report, which examines whether current health policies in Australia, China, India, Japan and South Korea are coping with the sharp rise of NCDs while these countries continue to tackle an existing burden of infectious diseases, such as tuberculosis and hepatitis.

There is a quote in the report by Professor Aikichi Iwamoto, chair of Japan’s National HIV Surveillance Committee, who notes that one difficulty in dealing with the HIV/AIDS epidemic in much of Asia is that “health systems in many countries are more adjusted to acute infections where people are cured by antimicrobials in five days.”

This accurately captures the history of a region that has endured deadly emergency outbreaks of viruses and influenzas for more than a century, most recently with SARS and Avian Flu.

Read More

September 28th, 2015

Janssen Teams Up With Sports Stars For AFib Awareness

Editor’s note: Atrial fibrillation, or AFib, is a type of irregular heart beat. It can sometimes be felt as a fluttering or “thumping” in the chest. Since the heart isn’t pumping properly, blood may pool in the upper chambers and form a clot. This clot can break free, travel to the brain, and cause a stroke.

In honor of AFib Awareness Month, 39-Time Grand Slam Tennis Champion Billie Jean King and 14-Time Basketball All-Star Jerry West are working with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to help raise awareness about this health condition. Below, they share their stories. Plus, read on for a simple tool to help you evaluate your risk.

Jerry’s Story

When I hit the court as a Los Angeles Laker, I loved the feeling of making a game-winning play and knowing I was on top of my game. But when I had to start breathing into a paper bag during games to keep from hyperventilating and my heart felt out-of-rhythm, I knew something was wrong. It wasn’t until after I stopped playing professional basketball that I was diagnosed with atrial fibrillation (AFib), an irregular heartbeat and one of the most common serious heart rhythm disorders in people over the age of 65.

Read More

June 16th, 2015

Cancer and Clots: An Unrecognized and Under-Researched Patient Burden

By Paul Burton, MD, PhD, Vice President, Medical Affairs, Janssen

More than one-third of all men and women in the United States will be diagnosed with cancer over the course of their lives. Living with cancer, the treatments and their side effects are significant burdens on their own. What many people with cancer often don’t realize is they are up to five times more likely to develop life-threatening blood clots than people the same age without cancer. These clots can occur deep in the veins in many parts of the body and sometimes travel to the lungs, a condition called venous thromboembolism (VTE). This risk is even more pronounced when patients with cancer undergo chemotherapy.

Blood clots are the second-leading cause of death in patients with cancer. We need a better understanding of how we can treat and prevent them, particularly for a large number of the one million patients who are treating their cancer outside the hospital.

That’s why the Janssen Pharmaceutical Companies of Johnson & Johnson, in conjunction with Bayer HealthCare, are furthering our commitment to addressing the most important unmet medical needs of our time by initiating a new research program: CALLISTO. CALLISTO is aimed at generating new evidence in the prevention and treatment of blood clots in patients with a wide range of cancer types.

Read More

May 19th, 2015

JanssenAWorldFreeFrom

Janssen Recognizes World IBD Day

By Scott Plevy, M.D., Disease Area Stronghold Leader, Inflammatory Bowel Disease (IBD), and Sean Larkin, Disease Area Stronghold Commercial Leader, IBD, Janssen

 Today, May 19th, the Janssen Pharmaceutical Companies of Johnson & Johnson recognize World Inflammatory Bowel Disease (IBD) Day, an annual event to raise awareness and support the five million people living with Crohn’s disease and ulcerative colitis (UC).

At Janssen, we work each and every day to improve the lives of people living with Crohn’s disease and UC—a passion that’s inspired us for more than two decades.

Guided by the conviction that there are no limits to science, we recognize that, despite our successes, we can do more for patients. As innovators and collaborators, we are committed to treating, intercepting and, one day, curing IBD.

We hope that you support World IBD Day and join the conversation on Twitter and LinkedIn by sharing what a world free from IBD means to you using #aworldfreefrom.


ScottPlevyJNJScott Plevy, M.D., is Vice President, Disease Area Stronghold Leader, IBD, Immunology Therapeutic Area, Janssen Research & Development, LLC.

 

 

Sean Larkin - Immunology - Comm DAS Lead_jpgSean Larkin is Vice President, Disease Area Stronghold Commercial Leader, Pulmonary and IBD, Janssen Global Services, LLC.

Read More